Markets:

Overview

News

Currencies

International

Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

455.24 -5.35 (-1.16%)

Streaming Delayed Price Updated: 3:39 PM EST, Jan 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

69 70 Next >

Is Vertex Pharmaceuticals Gaining or Losing Market Support? ↗

February 25, 2025

Via Benzinga

Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 15 Years ↗

February 24, 2025

Via Benzinga

3 Magnificent Growth Stocks to Buy Right Now ↗

February 22, 2025

Via The Motley Fool

2 No-Brainer Healthcare Stocks to Buy With $500 Right Now ↗

February 21, 2025

Via The Motley Fool

Analyst Expectations For Vertex Pharmaceuticals's Future ↗

February 20, 2025

Via Benzinga

Vertex to Participate in Upcoming March Investor Conferences

February 18, 2025

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex Pharmaceuticals Analysts Increase Their Forecasts After Q4 Results ↗

February 11, 2025

Via Benzinga

Vertex: Strong Sales, Stronger Pipeline ↗

February 11, 2025

Via The Motley Fool

3 Stocks That Could Trounce the Market in 2025 ↗

February 17, 2025

Via The Motley Fool

2 Healthcare Stocks That Tumbled in 2024...but Could See an Impressive Comeback in 2025 ↗

February 15, 2025

Via The Motley Fool

The Ultimate Healthcare Stock to Buy With $500 Right Now ↗

February 14, 2025

Via The Motley Fool

Vertex Pharmaceuticals Gets a Huge FDA Approval Which Could Send the Stock Skyrocketing ↗

February 14, 2025

Via The Motley Fool

Moderna (MRNA) Q4 Earnings Report Preview: What To Look For

February 13, 2025

Biotechnology company Moderna (NASDAQ:MRNA) will be announcing earnings results tomorrow before market open. Here’s what to expect.

Via StockStory

Why CRISPR Therapeutics Stock Was a Massive Winner on Wednesday ↗

February 12, 2025

Via The Motley Fool

This NXP Semiconductors Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday ↗

February 12, 2025

Via Benzinga

Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain. ↗

February 11, 2025

The company is entering a year of commercial launches. Those aren't guaranteed to put up cystic fibrosis-like numbers.

Via Investor's Business Daily

Biogen (BIIB) Reports Earnings Tomorrow: What To Expect

February 11, 2025

Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow morning. Here’s what to look for.

Via StockStory

Vertex Pharma Stock Flooded With Price-Target Hikes After Upbeat Q4 Revenue, 2025 Outlook: Retail Stays Bullish ↗

February 11, 2025

The company is betting on strong sales of its cystic fibrosis drugs and early traction from its newly approved non-opioid painkiller.

Via Stocktwits

Markets Steady, Positive; Q4 Earnings Keep Rolling ↗

February 10, 2025

Markets were flat but positive in an initial trading day for a new week, basically shrugging off whatever warning signs may have been considered regarding President Trump’s 25% steel tariff headline...

Via Talk Markets

Topics Government Stocks / Equities World Trade

Vertex Pharmaceuticals (VRTX) Q4 2024 Earnings Call Transcript ↗

February 10, 2025

VRTX earnings call for the period ending December 31, 2024.

Via The Motley Fool

Topics Earnings

Vertex's Revenue Surges but EPS Slips ↗

February 10, 2025

The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.

Via The Motley Fool

Vertex Pharmaceuticals’s (NASDAQ:VRTX) Q4 Sales Top Estimates

February 10, 2025

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q4 CY2024 results exceeding the market’s revenue expectations, with sales up 15.7% year on year to $2.91 billion. The company expects the...

Via StockStory

Vertex Reports Fourth Quarter and Full Year 2024 Financial Results

February 10, 2025

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex Q4 Earnings On Deck: Will This Biotech Heavyweight Keep Its Edge? ↗

February 10, 2025

Vertex Pharmaceuticals (VRTX) reports Q4 earnings today. Investors are eager for updates on new drug launches and growth potential. Stock has bullish technicals but risks remain.

Via Benzinga

Top Wall Street Forecasters Revamp Vertex Pharmaceuticals Price Expectations Ahead Of Q4 Earnings ↗

February 10, 2025

Via Benzinga

US Stocks To Open On A Positive Note After A String Of Bad Mondays: Recent Dip Has 'Reached Its Low Point,' Says Technical Analyst ↗

February 10, 2025

U.S. stock futures rose on Monday following Friday's sharp fall as investors digest tariff updates and earnings reports.

Via Benzinga

Topics World Trade

McDonald's, ON Semiconductor And 3 Stocks To Watch Heading Into Monday ↗

February 10, 2025

Stock futures up, focus on McDonald's, ON Semiconductor, VOXX, Rockwell Automation, Vertex Pharmaceuticals.

Via Benzinga

2 Biotech Stocks to Buy Hand Over Fist in February ↗

February 09, 2025

Via The Motley Fool

Earnings Scheduled For February 10, 2025 ↗

February 10, 2025

Via Benzinga

Vertex Pharmaceuticals (VRTX) Q4 Earnings Report Preview: What To Look For

February 09, 2025

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here’s what to look for.

Via StockStory

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

69 70 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.